<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ORBIVAN- butalbital, acetaminophen and caffeine capsule </strong><br>Atley Pharmaceuticals, Inc.<br></p></div>
<h1>Butalbital, Acetaminophen, and Caffeine Capsules<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f4f950f5-b404-416e-af93-a2fb031cc698"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ORBIVAN™ Butalbital, Acetaminophen and Caffeine Capsules USP are supplied in hard-gelatin capsule form for oral administration.</p>
<p>Each capsule contains the following active ingredients:</p>
<p>Butalbital USP……………………50 mg<br>Acetaminophen USP…………….300 mg<br>Caffeine USP……………………..40 mg</p>
<p><span class="Italics">Inactive Ingredients: </span>sodium lauryl sulfate, talc, microcrystalline cellulose, stearic acid, d&amp;c yellow # 10, fd&amp;c red#40, titanium dioxide, fd&amp;c blue#1, fd&amp;c yellow #6, gelatin.</p>
<p>Butalbital (5-allyl-5-isobutylbarbituric acid), is a short to intermediate-acting barbiturate of molecular weight 212.25. It has the following structural formula:</p>
<p><img alt="Butalbital Molecule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3c69436-a681-4e00-8db0-8cbfaac9627e&amp;name=d3c69436-a681-4e00-8db0-8cbfaac9627e-03.jpg"></p>
<p>Acetaminophen (4´-hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic of molecular weight 151.16. It has the following structural formula:</p>
<p><img alt="Acetaminophen Moleclue" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3c69436-a681-4e00-8db0-8cbfaac9627e&amp;name=d3c69436-a681-4e00-8db0-8cbfaac9627e-01.jpg"></p>
<p>Caffeine (1,3,7-trimethylxanthine), is a central nervous system stimulant of molecular weight 194.19. It has the following structural formula: </p>
<p><img alt="Caffeine Molecule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3c69436-a681-4e00-8db0-8cbfaac9627e&amp;name=d3c69436-a681-4e00-8db0-8cbfaac9627e-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9f800ea1-89bb-4859-b189-83ff41d66c60"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">This combination drug product is intended as a treatment for <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span>.</p>
<p>It consists of a fixed combination of butalbital, acetaminophen, and caffeine. The role each component plays in the relief of the complex of symptoms known as <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> is incompletely understood.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f90071c3-8370-434f-84dc-acf4ac555ddb"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The behavior of the individual components is described below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_51c2dab9-af8b-4d64-ab49-e148c265b1c3"></a><a name="section-2.1.1"></a><p></p>
<h3>Butalbital</h3>
<p class="First">Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.</p>
<p>Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2, 3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.</p>
<p>The <span class="Italics">in vitro </span>plasma protein binding of butalbital is 45% over the concentration range of 0.5-20 mcg/mL. This <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> within the range of plasma protein binding (20%-45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity, indicating that there is no preferential distribution of butalbital into either plasma or blood cells.</p>
<p>See <span class="Bold"><a href="#i4i_overdosage_id_05abd246-ae50-4743-89cb-7ad2e9585c6d">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2d05f6c-8963-4b50-96e6-7e9afaeefe17"></a><a name="section-2.1.2"></a><p></p>
<h3>Acetaminophen</h3>
<p class="First">Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.</p>
<p>See <span class="Bold"><a href="#i4i_overdosage_id_05abd246-ae50-4743-89cb-7ad2e9585c6d">OVERDOSAGE</a></span> for toxicity information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bbac81f-74be-4dbd-85a3-2cc1acc0b667"></a><a name="section-2.1.3"></a><p></p>
<h3>Caffeine</h3>
<p class="First">Like most xanthines, caffeine is rapidly absorbed and distributed in all body tissues and fluids, including the CNS, fetal tissues, and breast milk.</p>
<p>Caffeine is cleared through metabolism and excretion in the urine. The plasma half-life is about 3 hours. Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid. Of the 70% of the dose that is recovered in the urine, only 3% is unchanged drug.</p>
<p>See<span class="Bold"><a href="#i4i_overdosage_id_05abd246-ae50-4743-89cb-7ad2e9585c6d"> OVERDOSAGE</a></span> for toxicity information.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_01922fba-ac31-42d4-9ab9-f58f19fc057d"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ORBIVAN™ Butalbital, Acetaminophen and Caffeine capsules are indicated for the relief of the symptom complex of <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> (or muscle contraction) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_86db6dae-330c-4c3c-ba67-80fc4e57f684"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product is contraindicated under the following conditions:</p>
<p>– <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or intolerance to any component of this product</p>
<p>– Patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_9b162b50-9c0b-4b12-bb61-712f4af49af5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_13e157dc-9708-4c42-a840-a7c5bed4609d"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_e1183844-f002-4a83-805f-1be7aaa377eb"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">ORBIVAN™ Butalbital, acetaminophen, and caffeine capsules should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ecfb1af6-9e06-481a-86c6-7f79e5d5c70c"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.</p>
<p>Alcohol and other CNS depressants may produce an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> when taken with this combination product, and should be avoided.</p>
<p>Butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.</p>
<p>For information on use in geriatric patients, see<span class="Bold"><a href="#i4i_geriatric_use_id_692732aa-a69a-42da-97e7-2d5dff0f3867"> PRECAUTIONS/Geriatric Use</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_8f3eb8d5-6a24-4dda-b352-87ebd4fad109"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In patients with severe hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, effects of therapy should be monitored with serial liver and/or renal function tests.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_2da06109-f49d-469e-a16d-3405810c656b"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.</p>
<p>Butalbital, acetaminophen, and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_d43600d8-bfc5-4f8a-8093-d5b2290b402f"></a><a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_37d18382-abf2-45a6-a688-6ba9f8cfb52c"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether acetaminophen or butalbital have a potential for carcinogenesis, mutagenesis or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_974c1db0-506f-4bc8-8ca6-c7bb6b2d2364"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_9e29019d-58c0-4509-ae41-c21147ea2a03"></a><a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First"><span class="Italics">Pregnancy Category C: </span>Animal reproduction studies have not been conducted with this combination product. It is also not known whether butalbital, acetaminophen, and caffeine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only when clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_41e5c0c1-e36c-4ae8-93fa-f087e7fe9015"></a><a name="section-6.7.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4218977" conceptname="Drug withdrawal seizure">Withdrawal seizures</span> were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last two months of pregnancy. Butalbital was found in the infant’s serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> or other withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_57a46d07-1b62-45c4-a8b4-8056d7f4c52e"></a><a name="section-6.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caffeine, barbiturates, and acetaminophen are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from butalbital, acetaminophen, and caffeine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_52682e1a-1b2a-442b-86e7-8a82adc96f18"></a><a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_692732aa-a69a-42da-97e7-2d5dff0f3867"></a><a name="section-6.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of butalbital, acetaminophen and caffeine capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Butalbital is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_492e1207-cfb8-491f-90d7-f85676692466"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4c5dfa1-b224-48a3-8153-ba4f8e2a61c2"></a><a name="section-7.1"></a><p></p>
<h2>Frequently Observed</h2>
<p class="First">The most frequently reported adverse reactions are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and intoxicated feeling.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a64e8654-24dd-4ec9-8e16-78d97af85085"></a><a name="section-7.2"></a><p></p>
<h2>Infrequently Observed</h2>
<p class="First">All adverse events tabulated below are classified as infrequent.</p>
<p><span class="Bold"><span class="Italics">Central Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, shaky feeling, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, heavy eyelids, high energy, hot spells, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdosage of butalbital.</p>
<p><span class="Bold"><span class="Italics">Autonomic Nervous System: </span></span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>.</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal: </span></span>difficulty swallowing, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular: </span></span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal: </span></span><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>.</p>
<p><span class="Bold"><span class="Italics">Genitourinary: </span></span><span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
<p><span class="Bold"><span class="Italics">Miscellaneous: </span></span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p>Several cases of dermatological reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, have been reported.</p>
<p><span class="Bold">The following adverse drug events may be borne in mind as potential effects of the components of this product. Potential effects of high dosage are listed in the </span><span class="Bold"><a href="#i4i_overdosage_id_05abd246-ae50-4743-89cb-7ad2e9585c6d">OVERDOSAGE</a></span><span class="Bold"> section.</span></p>
<p><span class="Bold"><span class="Italics">Acetaminophen: </span></span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p><span class="Bold"><span class="Italics">Caffeine: </span></span>cardiac stimulation, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_a6aa946b-7f35-4588-92e9-8397c0c3a7fd"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_b5cb554b-3d8c-4bcc-8d50-81c28c7a2192"></a><a name="section-8.1"></a><p></p>
<h2>Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a13f3a6f-a2dc-45b4-8888-9c07c0869e78"></a><a name="section-8.1.1"></a><p></p>
<h3>Butalbital</h3>
<p class="First"><span class="Bold"><span class="Italics">Barbiturates may be habit-forming: </span></span>Tolerance, psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient’s regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_05abd246-ae50-4743-89cb-7ad2e9585c6d"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage of butalbital, acetaminophen, and caffeine, toxicity may result from the barbiturate or the acetaminophen. Toxicity due to caffeine is less likely, due to the relatively small amounts in this formulation.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fea71526-c2be-49e7-a966-bdcbe3274728"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from <span class="Bold"><span class="Italics">barbiturate </span></span><span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; and <span class="product-label-link" type="condition" conceptid="4192647" conceptname="Hypovolemic shock">hypovolemic shock</span>.</p>
<p>In <span class="Bold"><span class="Italics">acetaminophen </span></span>overdosage: dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. Renal tubular necroses, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. In adults hepatic toxicity has rarely been reported with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> of less than 10 grams, or fatalities with less than 15 grams.</p>
<p>Acute <span class="Bold"><span class="Italics">caffeine </span></span><span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may cause <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1aca6e69-7c08-4ae2-8a37-79ba686f8cbd"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">A single or multiple <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with this combination product is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended.</p>
<p>Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is usually hypovolemic and should respond to fluids. Pressors should be avoided. A cuffed endotracheal tube should be inserted before gastric lavage of the <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span> patient and when necessary, to provide assisted respiration. If renal function is normal, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, especially phenobarbital.</p>
<p>Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, peritoneal dialysis, or preferably hemodialysis may be considered. If <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> occurs due to acetaminophen <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, vitamin K should be administered intravenously.</p>
<p>If the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible. Serum acetaminophen levels should be obtained, since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals.</p>
<p><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> over 30% should be treated with methylene blue by slow intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3bdcc1c1-a2ad-4c31-b604-4df147486528"></a><a name="section-9.3"></a><p></p>
<h2>Toxic Doses (for adults)</h2>
<a name="id_285ecdbc-ee8e-4e59-b12d-5d31f92b710e"></a><table width="0.000">
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top">Butalbital:</td>
<td class="Botrule Rrule" align="left" valign="top">   toxic dose</td>
<td class="Botrule Rrule" align="left" valign="top">           1 g</td>
<td class="Botrule" align="left" valign="top">       (20 capsules)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Acetaminophen:</td>
<td class="Botrule Rrule" align="left" valign="top">   toxic dose</td>
<td class="Botrule Rrule" align="left" valign="top">         10 g</td>
<td class="Botrule" align="left" valign="top">       (33 capsules)</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Caffeine:</td>
<td class="Rrule" align="left" valign="top">   toxic dose</td>
<td class="Rrule" align="left" valign="top">           1 g</td>
<td class="Botrule" align="left" valign="top">       (25 capsules)</td>
</tr>
</tbody>
</table>
<p class="First">In all cases of suspected overdosage, call your Regional Poison Control Center to obtain the most up-to-date information about the treatment of overdosage. Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians’ Desk Reference<span class="Sup">®</span>*.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_9f6bae50-0fd1-488a-904e-604dc3691ba6"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">One or 2 capsules every 4 hours as needed. Total daily dosage should not exceed 6 capsules.</p>
<p>Extended and repeated use of this product is not recommended because of the potential for physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e76ab84a-2576-4159-8bea-6e2b22a42da4"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">ORBIVAN™ Butalbital, Acetaminophen, and Caffeine Capsules USP 50 mg/300 mg/40 mg</span></p>
<p>Containing 50 mg butalbital, 300 mg acetaminophen, and 40 mg caffeine. Available as hard gelatin capsules with a green cap, printed with AP, and a yellow body, printed with 661. The capsules are supplied in bottles of 100 capsules (NDC 59702-661-01) and in unit dose pouches for patient trial available only through physician offices [NDC 59702-661-12].</p>
<p>Store at 20 to 25<span class="Sup">o </span>C (68 to 77<span class="Sup">o</span> F) [see USP Controlled Room Temperature]; </p>
<p>Dispense in a tight, light-resistant container.</p>
<p>*Trademark of Medical Economics Company, Inc.</p>
<p><span class="Bold">Rx only</span></p>
<p>Mfg. for: </p>
<p><span class="Bold">Atley Pharmaceuticals, Inc.</span></p>
<p>Ashland, VA 23005</p>
<p>7029 Rev. 03/10</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4b373930-5e6d-4b78-9a91-715fd5cb8cd4"></a><a name="section-12"></a><p></p>
<h1>IMMEDIATE CONTAINER LABEL</h1>
<p class="First"><img alt="100 Count Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3c69436-a681-4e00-8db0-8cbfaac9627e&amp;name=d3c69436-a681-4e00-8db0-8cbfaac9627e-04.jpg"></p>
<p><span class="Bold">100 Count Container Label [ECL]</span></p>
<p><span class="Bold"><img alt="Unit Dose Pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3c69436-a681-4e00-8db0-8cbfaac9627e&amp;name=d3c69436-a681-4e00-8db0-8cbfaac9627e-05.jpg"><br>                                            [Front]                                [Back]<br>Unit Dose Pouch</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORBIVAN 		
					</strong><br><span class="contentTableReg">butalbital, acetaminophen, and caffeine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59702-661</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUTALBITAL</strong> (BUTALBITAL) </td>
<td class="formItem">BUTALBITAL</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem">ACETAMINOPHEN</td>
<td class="formItem">300 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAFFEINE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (Dark Green Cap) , YELLOW (Yellow Body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Hard Gelatin Capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;661</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59702-661-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:59702-661-12</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040885</td>
<td class="formItem">04/23/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Atley Pharmaceuticals, Inc.
							(928666536)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d3c69436-a681-4e00-8db0-8cbfaac9627e</div>
<div>Set id: d3c69436-a681-4e00-8db0-8cbfaac9627e</div>
<div>Version: 1</div>
<div>Effective Time: 20100423</div>
</div>
</div> <div class="DistributorName">Atley Pharmaceuticals, Inc.</div></p>
</body></html>
